These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. Bhargava S; Hotz B; Hines OJ; Reber HA; Buhr HJ; Hotz HG J Gastrointest Surg; 2007 Feb; 11(2):171-8. PubMed ID: 17390169 [TBL] [Abstract][Full Text] [Related]
4. An improved clinical model of orthotopic pancreatic cancer in immunocompetent Lewis rats. Hotz HG; Reber HA; Hotz B; Foitzik T; Buhr HJ; Cortina G; Hines OJ Pancreas; 2001 Mar; 22(2):113-21. PubMed ID: 11249064 [TBL] [Abstract][Full Text] [Related]
5. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046 [TBL] [Abstract][Full Text] [Related]
6. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215 [TBL] [Abstract][Full Text] [Related]
7. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice. Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066 [TBL] [Abstract][Full Text] [Related]
9. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer. El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584 [TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Dobrzanski P; Hunter K; Jones-Bolin S; Chang H; Robinson C; Pritchard S; Zhao H; Ruggeri B Cancer Res; 2004 Feb; 64(3):910-9. PubMed ID: 14871820 [TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. Kim S; Toyokawa H; Yamao J; Satoi S; Yanagimoto H; Yamamoto T; Hirooka S; Yamaki S; Inoue K; Matsui Y; Kwon AH Pancreas; 2014 Aug; 43(6):886-90. PubMed ID: 24717824 [TBL] [Abstract][Full Text] [Related]
12. Activation of alpha-smooth muscle actin-positive myofibroblast-like cells after chemotherapy with gemcitabine in a rat orthotopic pancreatic cancer model. Yamao J; Toyokawa H; Kim S; Yamaki S; Satoi S; Yanagimoto H; Yamamoto T; Hirooka S; Matsui Y; Kwon AH J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):206-13. PubMed ID: 23179559 [TBL] [Abstract][Full Text] [Related]
13. EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin. Shankar S; Marsh L; Srivastava RK Mol Cell Biochem; 2013 Jan; 372(1-2):83-94. PubMed ID: 22971992 [TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Zhang X; Galardi E; Duquette M; Lawler J; Parangi S Clin Cancer Res; 2005 Aug; 11(15):5622-30. PubMed ID: 16061881 [TBL] [Abstract][Full Text] [Related]
15. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. Erstad DJ; Sojoodi M; Taylor MS; Ghoshal S; Razavi AA; Graham-O'Regan KA; Bardeesy N; Ferrone CR; Lanuti M; Caravan P; Tanabe KK; Fuchs BC Dis Model Mech; 2018 Jul; 11(7):. PubMed ID: 29903803 [TBL] [Abstract][Full Text] [Related]
16. Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Craven KE; Gore J; Korc M Cancer Lett; 2016 Oct; 381(1):201-10. PubMed ID: 26723874 [TBL] [Abstract][Full Text] [Related]
17. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Aikawa T; Gunn J; Spong SM; Klaus SJ; Korc M Mol Cancer Ther; 2006 May; 5(5):1108-16. PubMed ID: 16731742 [TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model. Alves F; Borchers U; Padge B; Augustin H; Nebendahl K; Klöppel G; Tietze LF Cancer Lett; 2001 Apr; 165(2):161-70. PubMed ID: 11275365 [TBL] [Abstract][Full Text] [Related]
19. Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo. Brockschmidt C; Hirner H; Huber N; Eismann T; Hillenbrand A; Giamas G; Radunsky B; Ammerpohl O; Bohm B; Henne-Bruns D; Kalthoff H; Leithäuser F; Trauzold A; Knippschild U Gut; 2008 Jun; 57(6):799-806. PubMed ID: 18203806 [TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Schwarz RE; Awasthi N; Konduri S; Caldwell L; Cafasso D; Schwarz MA Cancer Biol Ther; 2010 Apr; 9(8):632-9. PubMed ID: 20212356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]